These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 32161193)

  • 1. C3a receptor blockade protects podocytes from injury in diabetic nephropathy.
    Morigi M; Perico L; Corna D; Locatelli M; Cassis P; Carminati CE; Bolognini S; Zoja C; Remuzzi G; Benigni A; Buelli S
    JCI Insight; 2020 Mar; 5(5):. PubMed ID: 32161193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shiga Toxin 2 Triggers C3a-Dependent Glomerular and Tubular Injury through Mitochondrial Dysfunction in Hemolytic Uremic Syndrome.
    Buelli S; Locatelli M; Carminati CE; Corna D; Cerullo D; Imberti B; Perico L; Brigotti M; Abbate M; Zoja C; Benigni A; Remuzzi G; Morigi M
    Cells; 2022 May; 11(11):. PubMed ID: 35681450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement.
    Locatelli M; Buelli S; Pezzotta A; Corna D; Perico L; Tomasoni S; Rottoli D; Rizzo P; Conti D; Thurman JM; Remuzzi G; Zoja C; Morigi M
    J Am Soc Nephrol; 2014 Aug; 25(8):1786-98. PubMed ID: 24578132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-reactive protein inhibits C3a/C3aR-dependent podocyte autophagy in favor of diabetic kidney disease.
    Zhang L; Li W; Gong M; Zhang Z; Xue X; Mao J; Zhang H; Li S; Liu X; Wu F; Shi J; Fu G
    FASEB J; 2022 Jun; 36(6):e22332. PubMed ID: 35503088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement C3a and C3a Receptor Activation Mediates Podocyte Injuries in the Mechanism of Primary Membranous Nephropathy.
    Gao S; Cui Z; Zhao MH
    J Am Soc Nephrol; 2022 Sep; 33(9):1742-1756. PubMed ID: 35777783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained activation of C3aR in a human podocyte line impairs the morphological maturation of the cells.
    Zheng JM; Wang SS; Tian X; Che DJ
    Mol Med Rep; 2020 Dec; 22(6):5326-5338. PubMed ID: 33174024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C3a receptor antagonist ameliorates inflammatory and fibrotic signals in type 2 diabetic nephropathy by suppressing the activation of TGF-β/smad3 and IKBα pathway.
    Li L; Yin Q; Tang X; Bai L; Zhang J; Gou S; Zhu H; Cheng J; Fu P; Liu F
    PLoS One; 2014; 9(11):e113639. PubMed ID: 25422985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOXO3a accumulation and activation accelerate oxidative stress-induced podocyte injury.
    Chen X; Liu W; Xiao J; Zhang Y; Chen Y; Luo C; Huang Q; Peng F; Gong W; Li S; He X; Zhuang Y; Wu N; Liu Y; Wang Y; Long H
    FASEB J; 2020 Oct; 34(10):13300-13316. PubMed ID: 32786113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mangiferin prevents diabetic nephropathy progression and protects podocyte function via autophagy in diabetic rat glomeruli.
    Wang X; Gao L; Lin H; Song J; Wang J; Yin Y; Zhao J; Xu X; Li Z; Li L
    Eur J Pharmacol; 2018 Apr; 824():170-178. PubMed ID: 29444469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A previously unrecognized role of C3a in proteinuric progressive nephropathy.
    Morigi M; Locatelli M; Rota C; Buelli S; Corna D; Rizzo P; Abbate M; Conti D; Perico L; Longaretti L; Benigni A; Zoja C; Remuzzi G
    Sci Rep; 2016 Jun; 6():28445. PubMed ID: 27345360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deficiency of C3a receptor attenuates the development of diabetic nephropathy.
    Li XQ; Chang DY; Chen M; Zhao MH
    BMJ Open Diabetes Res Care; 2019; 7(1):e000817. PubMed ID: 31798904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Manipulating Sirtuin 3 pathway ameliorates renal damage in experimental diabetes.
    Locatelli M; Zoja C; Zanchi C; Corna D; Villa S; Bolognini S; Novelli R; Perico L; Remuzzi G; Benigni A; Cassis P
    Sci Rep; 2020 May; 10(1):8418. PubMed ID: 32439965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial effect on podocyte number in experimental diabetic nephropathy resulting from combined atrasentan and RAAS inhibition therapy.
    Hudkins KL; Wietecha TA; Steegh F; Alpers CE
    Am J Physiol Renal Physiol; 2020 May; 318(5):F1295-F1305. PubMed ID: 32249614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of podocyte lesion in patients with diabetic nephropathy: Wilms' tumor-1 protein used as a podocyte marker.
    Su J; Li SJ; Chen ZH; Zeng CH; Zhou H; Li LS; Liu ZH
    Diabetes Res Clin Pract; 2010 Feb; 87(2):167-75. PubMed ID: 19969384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C3a and C5a receptor antagonists ameliorate endothelial-myofibroblast transition via the Wnt/β-catenin signaling pathway in diabetic kidney disease.
    Li L; Chen L; Zang J; Tang X; Liu Y; Zhang J; Bai L; Yin Q; Lu Y; Cheng J; Fu P; Liu F
    Metabolism; 2015 May; 64(5):597-610. PubMed ID: 25682062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine 1 receptor activation protects mouse diabetic podocytes injury via regulating the PKA/NOX-5/p38 MAPK axis.
    Shao X; Zhang X; Hu J; Gao T; Chen J; Xu C; Wei C
    Exp Cell Res; 2020 Mar; 388(2):111849. PubMed ID: 31954110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Podocyte RNF166 deficiency alleviates diabetic nephropathy by mitigating mitochondria impairment and apoptosis via regulation of CYLD signal.
    Hongbo M; Yanjiao D; Shuo W; Kun S; Yanjie L; Mengmeng L
    Biochem Biophys Res Commun; 2021 Mar; 545():46-53. PubMed ID: 33545631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection of CTGF Antibody Against Diabetic Nephropathy in Mice Via Reducing Glomerular β-Catenin Expression and Podocyte Epithelial-Mesenchymal Transition.
    Dai HY; Ma LN; Cao Y; Chen XL; Shi H; Fan YP; Yang B
    J Cell Biochem; 2017 Nov; 118(11):3706-3712. PubMed ID: 28370212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy.
    Susztak K; Raff AC; Schiffer M; Böttinger EP
    Diabetes; 2006 Jan; 55(1):225-33. PubMed ID: 16380497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of PTEN promotes podocyte cytoskeletal rearrangement, aggravating diabetic nephropathy.
    Lin J; Shi Y; Peng H; Shen X; Thomas S; Wang Y; Truong LD; Dryer SE; Hu Z; Xu J
    J Pathol; 2015 May; 236(1):30-40. PubMed ID: 25641678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.